Half of the infections (53%) occurred in the first 100 days after CAR-T infusion. Most (92%) were mild-moderate and of the lower/upper respiratory tract system (68%). With a median follow-up of 6.0 months (95% confidence interval, 4.7-7.4), there were a total of 47 infection events in 29 (53%) patients: 40% bacterial, 53% viral, and 6% fungal. At 1 year after infusion, 76% patients had hypogammaglobulinemia. In the first month after CAR-T, 98% patients had grade 3 to 4 neutropenia. Most patients (68%) received bridging chemotherapy (BC) before LD. Before lymphodepletion (LD), 35% of patients had severe hypogammaglobulinemia and 18% had severe lymphopenia. Fifty-five patients with MM were treated with BCMA CAR-T. We performed a single-center retrospective analysis of infection outcomes up to 1 year after BCMA CAR-T for MM from 2018 to 2020. ![]() However, the pattern of infectious complications is not well elucidated. B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy (BCMA CAR-T) is an effective treatment of relapsed refractory multiple myeloma (MM).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
June 2023
Categories |